David Friedland

2.1k total citations
60 papers, 1.5k citations indexed

About

David Friedland is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, David Friedland has authored 60 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 25 papers in Pulmonary and Respiratory Medicine and 21 papers in Molecular Biology. Recurrent topics in David Friedland's work include Lung Cancer Research Studies (10 papers), Cancer therapeutics and mechanisms (9 papers) and Lung Cancer Treatments and Mutations (9 papers). David Friedland is often cited by papers focused on Lung Cancer Research Studies (10 papers), Cancer therapeutics and mechanisms (9 papers) and Lung Cancer Treatments and Mutations (9 papers). David Friedland collaborates with scholars based in United States, Greece and South Korea. David Friedland's co-authors include Chandra P. Belani, Ramesh K. Ramanathan, Suresh S. Ramalingam, Ronald G. Stoller, Sanjiv S. Agarwala, Athanassios Argiris, James D. Luketich, Robert L. Comis, Mark A. Socinski and Dwight E. Heron and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and PLoS ONE.

In The Last Decade

David Friedland

59 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Friedland United States 20 545 489 486 228 169 60 1.5k
Gerald J. Fetterly United States 24 901 1.7× 609 1.2× 378 0.8× 134 0.6× 63 0.4× 88 1.9k
Claire Goulvestre France 21 523 1.0× 201 0.4× 343 0.7× 260 1.1× 77 0.5× 52 1.9k
C.J. van Groeningen Netherlands 28 983 1.8× 1.4k 2.8× 483 1.0× 129 0.6× 133 0.8× 51 2.4k
Richard J. Honeywell Netherlands 26 1.0k 1.9× 822 1.7× 477 1.0× 167 0.7× 64 0.4× 77 1.9k
Christiane Thallinger Austria 25 876 1.6× 559 1.1× 206 0.4× 101 0.4× 66 0.4× 56 1.7k
Daniel Steinbach Germany 26 1.1k 2.0× 943 1.9× 160 0.3× 162 0.7× 206 1.2× 69 2.3k
Eric Scholar United States 18 893 1.6× 581 1.2× 222 0.5× 153 0.7× 98 0.6× 27 1.8k
Jan Eucker Germany 29 1.0k 1.9× 760 1.6× 182 0.4× 401 1.8× 378 2.2× 85 2.5k
Stephen M. Kelsey United Kingdom 27 1.3k 2.3× 908 1.9× 233 0.5× 216 0.9× 65 0.4× 75 2.9k
Eugene Mechetner United States 19 706 1.3× 1.0k 2.1× 144 0.3× 78 0.3× 222 1.3× 39 1.8k

Countries citing papers authored by David Friedland

Since Specialization
Citations

This map shows the geographic impact of David Friedland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Friedland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Friedland more than expected).

Fields of papers citing papers by David Friedland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Friedland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Friedland. The network helps show where David Friedland may publish in the future.

Co-authorship network of co-authors of David Friedland

This figure shows the co-authorship network connecting the top 25 collaborators of David Friedland. A scholar is included among the top collaborators of David Friedland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Friedland. David Friedland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, X., Erin M. Bertino, Scott Antonia, et al.. (2023). A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations. ESMO Open. 8(2). 101183–101183. 12 indexed citations
2.
Appleman, Leonard J., Theodore F. Logan, Daniel P. Normolle, et al.. (2018). Targeting autophagy and immunotherapy with hydroxychloroquine and interleukin 2 in patients with metastatic renal cell carcinoma (mRCC): A Cytokine Working Group study.. Journal of Clinical Oncology. 36(5_suppl). 106–106. 3 indexed citations
3.
Friedland, David, et al.. (2017). First-Line Osimertinib in Patients with Treatment-Naive Somatic or Germline EGFR T790M–Mutant Metastatic NSCLC. Journal of Thoracic Oncology. 13(1). e3–e5. 15 indexed citations
4.
Huang, Xingyue, Alena Jandourek, Phillip Cole, & David Friedland. (2013). Current Use of Ceftaroline for Community-Acquired Bacterial Pneumonia (CABP) in US Hospitals: Length of Stay and Total Cost From the CAPTURE Study. CHEST Journal. 144(4). 259A–259A. 4 indexed citations
5.
Ramalingam, Suresh S., Α. Kotsakis, Ahmad A. Tarhini, et al.. (2013). A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer. 81(3). 416–421. 17 indexed citations
6.
7.
Wu, Huali, Ramesh K. Ramanathan, Beth A. Zamboni, et al.. (2011). Population Pharmacokinetics of Pegylated Liposomal CKD‐602 (S‐CKD602) in Patients With Advanced Malignancies. The Journal of Clinical Pharmacology. 52(2). 180–194. 30 indexed citations
8.
Wu, Tong, et al.. (2008). Renal Cell Carcinoma from a Transplanted Allograft: Two Case Reports and a Review of the Literature. Clinical Genitourinary Cancer. 6(1). 53–55. 15 indexed citations
9.
Moschos, Stergios J., Christine Odoux, Stephanie R. Land, et al.. (2007). Endostatin plus interferon-α2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents. Melanoma Research. 17(3). 193–200. 19 indexed citations
10.
Janjic, Bratislav, Xiaofei Wang, Julien Fourcade, et al.. (2006). Spontaneous CD4+ T Cell Responses against TRAG-3 in Patients with Melanoma and Breast Cancers. The Journal of Immunology. 177(4). 2717–2727. 15 indexed citations
11.
Gerszten, Peter C., Steven A. Burton, Chandra P. Belani, et al.. (2006). Radiosurgery for the treatment of spinal lung metastases. Cancer. 107(11). 2653–2661. 47 indexed citations
12.
Kondziolka, Douglas, Juan J. Martin, John C. Flíckinger, et al.. (2005). Long‐term survivors after gamma knife radiosurgery for brain metastases. Cancer. 104(12). 2784–2791. 101 indexed citations
13.
Friedland, David, et al.. (2004). A Phase II Evaluation of Weekly Paclitaxel Plus Carboplatin in Advanced Urothelial Cancer. Cancer Investigation. 22(3). 374–382. 12 indexed citations
14.
Ramanathan, Ramesh K., Sakkaraiappan Ramalingam, Merrill J. Egorin, et al.. (2004). Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies. Cancer Chemotherapy and Pharmacology. 55(4). 354–360. 13 indexed citations
15.
Comis, Robert L., et al.. (1999). The Role of Oral Etoposide in Non-Small Cell Lung Cancer. Drugs. 58(Supplement 3). 21–30. 7 indexed citations
16.
Kovatich, Albert J., David Friedland, Teresa Druck, et al.. (1998). Molecular alterations to human chromosome 3p loci in neuroendocrine lung tumors. Cancer. 83(6). 1109–1117. 38 indexed citations
17.
McGee, Lesley, Keith P. Klugman, David Friedland, & Hoan Jong Lee. (1997). Spread of the Spanish Multi-Resistant Serotype 23F Clone of Streptococcus pneumoniae to Seoul, Korea. Microbial Drug Resistance. 3(3). 253–257. 33 indexed citations
18.
Treat, Joseph, et al.. (1996). Phase II Trial of All-Trans Retinoic Acid in Metastatic Non-Small Cell Lung Cancer. Cancer Investigation. 14(5). 415–420. 20 indexed citations
19.
20.
Ades, Ibrahim Z. & David Friedland. (1988). Properties of chicken erythrocyte delta-aminolevulinate synthase. International Journal of Biochemistry. 20(9). 965–969. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gerald J. Fetterly Breakdown of academic impact, for papers by Claire Goulvestre Breakdown of academic impact, for papers by C.J. van Groeningen Breakdown of academic impact, for papers by Richard J. Honeywell Breakdown of academic impact, for papers by Christiane Thallinger Breakdown of academic impact, for papers by Daniel Steinbach Breakdown of academic impact, for papers by Eric Scholar Breakdown of academic impact, for papers by Jan Eucker Breakdown of academic impact, for papers by Stephen M. Kelsey Breakdown of academic impact, for papers by Eugene Mechetner
Rankless by CCL
2026